Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors

References

• BaigentCKeechAKearneyPMEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536612677816214597
   PubMed Web of Science ®Google Scholar
• BariciakEDPlintACGabouryIDating of bruises in children: an assessment of physician accuracyPediatrics2003112804714523170
   PubMed Web of Science ®Google Scholar
• BaysHEzetimibeExpert Opin Investig Drugs20021115871604
   PubMed Web of Science ®Google Scholar
• BaysHEExtended-release niacin/lovastatin: the first combination product for dyslipidemiaExpert Rev Cardiovasc Ther2004248550115225109
   PubMedGoogle Scholar
• BaysHAdiposopathy – defining, diagnosing, and establishing indications to treat “sick fat”: what are the regulatory considerations?US Endocrine Disease2006a1214
   Google Scholar
• BaysHWhat are the long-term effects of statin therapy?Nat Clin Pract Cardiovasc Med2006b31289
   Google Scholar
• BaysHStatin safety: an overview and assessment of the data – 2005Am J Cardiol2006c976C26C
   PubMed Web of Science ®Google Scholar
• BaysHAbateNChandaliaMAdiposopathy: Sick fat causes high blood sugar, high blood pressure, and dyslipidemiaFuture Cardiology20051395919804060
   PubMedGoogle Scholar
• BaysHBallantyneCAdiposopathy: why do adiposity and obesity cause metabolic disease?Future Lipidology20061389420
   Web of Science ®Google Scholar
• BaysHBlondeLRosensonRAdiposopathy: How do diet, exercise, weight loss and drug therapies improve metabolic disease?Expert Rev Cardiovasc Ther2006c48719517173503
   PubMedGoogle Scholar
• BaysHECohenDERationale and design of a prospective clinical trial program to evaluate colesevelam’s glucose-lowering effects in patients with type 2 diabetes mellitusCurr Med Res Opin20072316738417588297
   PubMed Web of Science ®Google Scholar
• BaysHEDavidsonMJonesMREffects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemiaAm J Cardiol2006b971198120516616026
   PubMed Web of Science ®Google Scholar
• BaysHDujovneCColesevelam HCl: a non-systemic lipid-altering drugExpert Opin Pharmacother200347799012740000
   PubMed Web of Science ®Google Scholar
• BaysHEDujovneCAMcGovernMEComparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin. the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]Am J Cardiol2003916677212633795
   PubMed Web of Science ®Google Scholar
• BaysHDujovneCAAdiposopathy is a more rational treatment target for metabolic disease than obesity aloneCurr Atheroscler Rep200681445616510049
   PubMedGoogle Scholar
• BaysHEGoldbergRBTruittKAddition of colesevelam HCl to patients with type 2 diabetes mellitus inadequately controlled on a metformin-based therapy improves glycemic control2007Abstract poster Presentation American Association of Clinical Endocrinologists 16th Annual Meeting and Clinical CongressApril 14, 2007Seattle Washington USA
   Google Scholar
• BaysHEOseLFraserNA multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemiaClin Ther20042617587315639688
   PubMed Web of Science ®Google Scholar
• BaysHRhyneJAbbySLipid-lowering effects of colesevelam HCl in combination with ezetimibeCurr Med Res Opin2006a22219120017076980
   PubMed Web of Science ®Google Scholar
• BaysHSteinEAPharmacotherapy for dyslipidaemia – current therapies and future agentsExpert Opin Pharmacother2003419013814596646
   PubMed Web of Science ®Google Scholar
• BlankenhornDHNessimSAJohnsonRLBeneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass graftsJAMA19872573233403295315
   PubMed Web of Science ®Google Scholar
• BrendelCSchoonjansKBotrugnoOAThe small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activityMol Endocrinol20021620657612198243
   PubMed Web of Science ®Google Scholar
• BrensikeJFLevyRIKelseySFEffects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention StudyCirculation198469313246360414
   PubMed Web of Science ®Google Scholar
• BrownGAlbersJJFisherLDRegression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein BN Engl J Med19903231289982215615
   PubMed Web of Science ®Google Scholar
• CaoGLiangYBroderickCLAntidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesisJ Biol Chem20032781131612414791
   PubMed Web of Science ®Google Scholar
• Cashin-HemphillLMackWJPogodaJMBeneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-upJAMA19902643013172243429
   PubMed Web of Science ®Google Scholar
• DavidsonMHDifferences between clinical trial efficacy and real-world effectivenessAm J Manag Care200612S405S1117112328
   PubMed Web of Science ®Google Scholar
• DavidsonMHMakiKCPearsonTAResults of the National Cholesterol Education. NCEP. Program Evaluation ProjecT Utilizing Novel E-Technology. NEPTUNE. II survey and implications for treatment under the recent NCEP Writing Group recommendationsAm J Cardiol2005965566316098311
   PubMed Web of Science ®Google Scholar
• DevarajSAutretBJialalIEffects of colesevelam hydrochloride. WelChol. on biomarkers of inflammation in patients with mild hypercholesterolemiaAm J Cardiol200698641316923452
   PubMed Web of Science ®Google Scholar
• EfanovAMSewingSBokvistKLiver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cellsDiabetes200453Suppl 3S75S815561926
   PubMed Web of Science ®Google Scholar
• FlexmanAMDelVGSchwarzSKDark green blood in the operating theatreLancet2007369197217560450
   PubMed Web of Science ®Google Scholar
• FonsecaVRosenstockJTruittKColesevelam HCl added to sulfonylurea-based therapy in patients with inadequately controlled type 2 diabetes mellitus improves glycemic control2007Abstract poster presentation American Association of Clinical Endocrinologists 16th Annual Meeting and Clinical CongressApril 14th, 2007Seattle Washington USA
   Google Scholar
• FuLJohnLMAdamsSHFibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetesEndocrinology2004145259460314976145
   PubMed Web of Science ®Google Scholar
• GagneCBaysHEWeissSREfficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemiaAm J Cardiol20029010849112423708
   PubMed Web of Science ®Google Scholar
• GargAGrundySMCholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trialAnn Intern Med1994121416228053615
   PubMed Web of Science ®Google Scholar
• GoldbergRBTruittKColesevelam HCl improves glycemic control in type 2 diabetes mellitus subjects managed with insulin therapy2006Abstract poster presentation. American Heart Association Annual MeetingNovember 12–15, 2006Chicago Illinois USA
   Google Scholar
• GrundySMCleemanJIMerzCNImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation20041102273915249516
   PubMed Web of Science ®Google Scholar
• GuptaSPandakWMHylemonPBLXR alpha is the dominant regulator of CYP7A1 transcriptionBiochem Biophys Res Commun20022933384312054605
   PubMed Web of Science ®Google Scholar
• HofmannAFThe continuing importance of bile acids in liver and intestinal diseaseArch Intern Med199915926475810597755
   PubMed Web of Science ®Google Scholar
• HoltJALuoGBillinANDefinition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesisGenes Dev20031715819112815072
   PubMed Web of Science ®Google Scholar
• JanuviaStagliptin [online]2007 URL: http://www.januvia.com.
   Google Scholar
• JonesPKafonekSLauroraIComparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia. the CURVES studyAm J Cardiol19988158279514454
   PubMed Web of Science ®Google Scholar
• JonesPHRationale for intensive statin treatment in high-risk patientsPrev Cardiol2006991516603827
   PubMedGoogle Scholar
• KaneJPMalloyMJPortsTARegression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimensJAMA19902643007122243428
   PubMed Web of Science ®Google Scholar
• KerrTASaekiSSchneiderMLoss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesisDev Cell200227132012062084
   PubMed Web of Science ®Google Scholar
• LaffitteBAChaoLCLiJActivation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissueProc Natl Acad Sci USA200310054192412697904
   PubMed Web of Science ®Google Scholar
• Lipid Research ClinicsThe Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart diseaseJAMA1984a251351646361299
   PubMed Web of Science ®Google Scholar
• Lipid Research ClinicsThe Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol loweringJAMA1984b251365746361300
   PubMed Web of Science ®Google Scholar
• LundasenTGalmanCAngelinBCirculating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in manJ Intern Med2006260530617116003
   PubMed Web of Science ®Google Scholar
• MaKSahaPKChanLFarnesoid X receptor is essential for normal glucose homeostasisJ Clin Invest20061161102916557297
   PubMed Web of Science ®Google Scholar
• McKenneyJJonesMAbbySSafety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemiaCurr Med Res Opin20052114031216197659
   PubMed Web of Science ®Google Scholar
• MitroNMakPAVargasLThe nuclear receptor LXR is a glucose sensorNature20074452192317187055
   PubMed Web of Science ®Google Scholar
• [NCEP] National Cholesterol Education ProgramThird Report of the National Cholesterol Education Program. NCEP. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Adult Treatment Panel III. final reportCirculation2002106314342112485966
   PubMed Web of Science ®Google Scholar
• SeoJBMoonHMKimWSActivated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expressionMol Cell Biol20042434304415060163
   PubMed Web of Science ®Google Scholar
• ShibataSHayakawaKEgashiraYRoles of nuclear receptors in the up-regulation of hepatic cholesterol 7alpha-hydroxylase by cholestyramine in ratsLife Sci2007805465317107691
   PubMed Web of Science ®Google Scholar
• StayrookKRBramlettKSSavkurRSRegulation of carbohydrate metabolism by the farnesoid X receptorEndocrinology20051469849115564327
   PubMed Web of Science ®Google Scholar
• StrackAMMyersRWModulation of metabolic syndrome by fibroblast growth factor 19. FGF19?Endocrinology20041452591315140837
   PubMed Web of Science ®Google Scholar
• StulnigTMOppermannUSteffensenKRLiver X receptors downregulate 11beta-hydroxysteroid dehydrogenase type 1 expression and activityDiabetes20025124263312145154
   PubMed Web of Science ®Google Scholar
• TonstadSRole of lipid-lowering pharmacotherapy in childrenPaediatr Drugs20002112210937455
   PubMedGoogle Scholar
• TontonozPMangelsdorfDJLiver X receptor signaling pathways in cardiovascular diseaseMol Endocrinol2003179859312690094
   PubMed Web of Science ®Google Scholar
• VasudevanARJonesPHEffective use of combination lipid therapyCurr Atheroscler Rep20068768416455018
   PubMedGoogle Scholar
• WattsGFLewisBBruntJNEffects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study. STARSLancet199233956391347091
   PubMed Web of Science ®Google Scholar
• Welchol® Product InformationCholesevelam hydrochloride2007 Accessed July 1, 2007. URL: http://www.welchol.com/pdfs/fullPI.pdf
   Google Scholar
• YamakawaTTakanoTUtsunomiyaHEffect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemiaEndocr J20075453817102570
   PubMed Web of Science ®Google Scholar
• ZhangYLeeFYBarreraGActivation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic miceProc Natl Acad Sci USA200610310061116410358
   PubMed Web of Science ®Google Scholar
• ZieveFJKalinMFSchwartzSLResults of the glucose-lowering effect of WelChol study. GLOWS: A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetesClin Ther200729748317379048
   PubMed Web of Science ®Google Scholar